SCHEMBL16619826

SCHEMBL16619826

Cc1ccnc2c(C(=O)O)c(N)nn12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.44
PIK3R2 O00459 1/20 0.44
PIK3CG P48736 1/20 0.44
NTRK1 P04629 7/20 0.44
PIM1 P11309 7/20 0.44
ACVR1 Q04771 2/20 0.39
HTR6 P50406 2/20 0.39
PTGS2 P35354 1/20 0.37
CHEK1 O14757 1/20 0.36
CDK2 P24941 1/20 0.36
CSNK2A1 P68400 1/20 0.36
KDM5A P29375 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
ALDH1A1 P00352 2/20 0.36
PKM P14618 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15307095 0.82 NTRK1 (0.39) PIK3CDPIK3R2PIK3CGNTRK1PIM1
SCHEMBL16629068 0.81 TSHR (0.46) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL23013393 0.76 DHODH (0.46) PIK3CDPIK3R2PIK3CGNTRK1PIM1
SCHEMBL15307047 0.75 KDM4E (0.53) PIK3CGHTR6PTGS2NPC1RAB9A
SCHEMBL15307102 0.69 TSHR (0.48) NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL359062 0.69 KDM4E (0.57) PIM1KDM5AKDM4CKDM5BALDH1A1
SCHEMBL16619547 0.68 PIK3CG (0.45) PIK3CDPIK3R2PIK3CGAPOBEC3A
SCHEMBL1260539 0.67 NOS2 (0.52) KDM5ANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL23013654 0.67 ALDH1A1 (0.44) NTRK1PIM1ACVR1NPC1RAB9A
SCHEMBL31277907 0.67 NTRK1 (0.65) NTRK1PIM1ACVR1CHEK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9751888-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-09-05 US disclosed
US-9751888-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-09-05 US disclosed
US-9751888-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-09-05 US disclosed
US-20160222016-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2016-08-04 US disclosed
US-20160222016-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2016-08-04 US disclosed
US-20160222016-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2016-08-04 US disclosed
WO-2015051241-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. (US) 2015-04-09 WO disclosed
WO-2015051241-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222016-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB PIK3CD 2/4885PIK3R2 35/4885PIK3CG 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.